Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure.

@article{Cohen1998ProtectiveEO,
  title={Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure.},
  author={D. Cohen and J. Mathis and R. Dotson and S. R. Graybill and N. J. Wosu},
  journal={Journal of cardiovascular pharmacology},
  year={1998},
  volume={32 1},
  pages={
          87-95
        }
}
The purpose of these studies was to compare the effects of CGS 30440 (CGS), a dual angiotensin-converting enzyme inhibitor (ACEI)/neutral endopeptidase inhibitor (NEPI) to benazepril (BZ), an ACEI, in a model of five-sixths nephrectomy. The doses of BZ and CGS 30440 tested were 6.5 micromol/kg/day and 2.2 micromol/kg/day. Drugs or vehicle (V) were administered subcutaneously for 6 weeks with dosing initiated 1 week after renal mass reduction. At 6 weeks of receiving drug (7 weeks after five… Expand
Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats.
  • U. Wenzel, G. Wolf, +5 authors R. Stahl
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2003
Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy
...
1
2
3
...

References

SHOWING 1-10 OF 34 REFERENCES
Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.
Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.
Bradykinin-mediated effects of ACE inhibition.
...
1
2
3
4
...